U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07473323) titled 'Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease' on Feb. 26.
Brief Summary: This is a phase 1 randomized, double-blind, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and Pharmacokinetics (PK) of single and multiple ascending doses of MTX-439 administered in healthy adults and adults with diabetic kidney disease (DKD)
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Healthy Adult Participants
Diabetic Kidney Disease
Intervention:
BIOLOGICAL: MTX-439
MTX-439 is a recombinant human immunoglobulin G1 (IgG1) monoclonal antib...